Research
Title : | Towards development of a potent antiviral against SARS–CoV-2 by targeting the interaction between nucleocapsid protein and viral RNA |
Area of research : | COVID-19 Research, Life Sciences & Biotechnology |
Focus area : | COVID-19 Therapeutics |
Principal Investigator : | Dr Milan Surjit, Associate Professor, Translational Health Science and Technology Institute (THSTI), Faridabad |
Timeline Start Year : | 2020 |
Contact info : | milan@thsti.res.in |
Details
Executive Summary : | The study aims to explore novel therapeutic strategies against the COVID-19 by investigating the role of viral Nucleocapsid protein (N) in the life cycle of SARS-CoV-2 in two steps. |
Outcome/Output: | Cyclic peptides are one of the most promising therapeutic options, given that many of the existing drugs such as oxytocin, vasopressin (hormones), vancomycin, daptomycin (antibiotics) or cyclosporine (immunosuppressant) are cyclic peptides. Therefore, an inhibitor identified in the study holds significant therapeutic value for SARS-CoV-2. |
Organizations involved
Implementing Agency : | Translational Health Science and Technology Institute (THSTI), Faridabad Funding Agency :Department of Science and Technology (DST), Govt of India | |